{{Genetics sidebar}}

'''药物基因组学'''（{{lang-en|pharmacogenomics}}），又称'''基因组药物学'''或'''基因组药理学'''，是研究基因组在药物反应中的作用。药物基因组学分析个体的遗传构成如何影响他/她对药物的反应<ref>{{cite book|title=Emerging Medical Technologies|last=Ermak|first=Gennady|publisher=World Scientific|year=2015|isbn=978-981-4675-80-2|location= |via=}}</ref>。通过将[[基因表达|基因表达]]或[[单核苷酸多态性|单核苷酸多态性]]与[[药代动力学|药代动力学]]（药物的{{le|吸收 (药物代谢动力学)|Absorption (pharmacokinetics)|吸收}}，{{le|分布 (药理学)|Distribution (pharmacology)|分布}}，[[药物代谢|代谢]]，和{{le|清除率 (药理学)|Clearance (pharmacology)|消除}}）和[[药物效应动力学|药物效应动力学]]以及药物受体靶效应相关联，处理后天获得性的与先天性的遗传变异对药物反应的影响<ref name="pmid14585618">{{cite journal | author = Johnson JA | title = Pharmacogenetics: potential for individualized drug therapy through genetics. | journal = Trends Genet | volume = 19 | issue = 11 | pages = 660–6 | date = November 2003 | pmid = 14585618 | doi=10.1016/j.tig.2003.09.008}}</ref><ref name="UNC Center for Pharmacogenomics and Individualized Therapy">{{cite web| title=Center for Pharmacogenomics and Individualized Therapy| url=https://pharmacy.unc.edu/research/centers/cpit/| accessdate=2014-06-25| archive-date=2015-07-02| archive-url=https://web.archive.org/web/20150702034039/http://pharmacy.unc.edu/research/centers/cpit/| dead-url=no}}</ref><ref>{{cite web|title=overview of pharmacogenomics|publisher=Up-to-Date|url=http://www.uptodate.com/contents/overview-of-pharmacogenomics?source=search_result&search=pharmacogenomics&selectedTitle=1~15|date=May 16, 2014|accessdate=2014-06-25|archive-date=2016-10-05|archive-url=https://web.archive.org/web/20161005100200/http://www.uptodate.com/contents/overview-of-pharmacogenomics?source=search_result&search=pharmacogenomics&selectedTitle=1~15|dead-url=no}}</ref>。

药物基因组学根据患者的[[基因型|基因型]]来保证最大疗效的同时将[[不良反应_(医学)|不良反应]]降到最低，用于探索合理的方法来优化[[药物治疗|药物治疗]]方案<ref>Becquemont L (June 2009). "Pharmacogenomics of adverse drug reactions: practical applications and perspectives". Pharmacogenomics 10 (6): 961–9. doi:10.2217/pgs.09.37. PMID 19530963. </ref>。这样的方法许诺“[[精密医学|精密医学]]”（precision medicine）甚至“{{le|个体化治疗|Personalized medicine}}（personalized medicine）”的出现，其中药物和药物组合被优化来针对狭窄的患者子集，甚至针对每个人的独特遗传构成<ref>"Guidance for Industry Pharmacogenomic Data Submissions" (PDF). U.S. Food and Drug Administration. March 2005. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf {{Wayback|url=http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf |date=20090901130414 }}. Retrieved 2008-08-27.</ref><ref>Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Del Zompo M, Patrinos GP (August 2010). "Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice". Pharmacogenomics 11 (8): 1149–67. doi:10.2217/pgs.10.97. PMID 20712531.</ref>。无论是用来解释病人的反应还是缺乏治疗，或作为预测工具，都希望能够获得更好的治疗效果，更大的疗效，使药物毒性和药物不良反应（ADR）发生的最小化。对于对治疗缺乏治疗反应的患者，可以指定最适合其要求的替代疗法。为了提供给定药物的药物基因组建议，可以使用两种可能的输入类型：[[基因型分型|基因型分型]]或外显子或[[测序|全基因组测序]]<ref name=eval>{{cite journal |vauthors = Huser V, Cimino JJ | title = Providing pharmacogenomics clinical decision support using whole genome sequencing data as input | journal = AMIA Summits on Translational Science Proceedings | volume = 2013 | page = 81 | year = 2013 | pmid = 24303303 }}</ref>。测序提供了更多的数据点，包括检测过早终止合成蛋白（早期[[终止密码子|终止密码子]]）的突变<ref name="eval" />。

== 参考文献 ==
{{Reflist}}

== 参见 ==
{{portal|生物学|生物技术|医学}}
* [[基因組學|基因組學]]
* [[基因工程|基因工程]]

{{-}}
{{基因组学}}
{{个人基因组学}}
{{药理学}}

[[Category:基因組學|Category:基因組學]]
[[Category:藥理學|Category:藥理學]]
[[Category:藥學|Category:藥學]]